• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

    11/2/23 6:30:00 AM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGN alert in real time by email

    Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3

    ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA

    PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024

    Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China

    Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer

    Conference Call to be Held at 8:00 a.m. ET Today

    ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

    "Building on the momentum generated in the first half of 2023, we delivered a strong third quarter highlighted by significant ELAHERE revenue growth and the achievement of key operational milestones," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "With a 36% increase in sequential quarterly net sales and over $210 million in product revenue through the first nine months of the year, ELAHERE is tracking towards one of the most successful first product launches in oncology in a decade. We also made important progress in our effort to bring ELAHERE to eligible patients around the world with the acceptance of the MAA by the EMA and the NDA by the NMPA, and the establishment of a collaboration with Takeda to deliver ELAHERE in Japan."

    Enyedy continued, "In addition, we advanced the ELAHERE development program and are pleased to report that our PICCOLO trial in platinum-sensitive ovarian cancer has met the primary endpoint of objective response rate based on an interim efficacy assessment. With a number of patients remaining on treatment and longer follow-up required to establish mature response durability of ELAHERE in this patient population, we anticipate an ORR of at least 48% when we report full data in mid-2024. Turning to our second pivotal program, PVEK, we continue to advance our 802 study and look forward to reporting data from our PVEK/VEN/AZA triplet in frontline AML at ASH in December. We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα. We look forward to a strong finish to the year and a productive 2024 with the continued growth of ELAHERE, important new data for our programs, and geographic expansion in Europe and China."

    RECENT PROGRESS

    ELAHERE (mirvetuximab soravtansine-gynx)

    • Generated $105.2 million in ELAHERE net sales for the quarter ended September 30, 2023.
    • Obtained acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for ELAHERE in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) to support approval and launch in Europe.
    • Submitted the supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) to support conversion to full approval.
    • Our partner, Huadong Medicine, obtained acceptance of the New Drug Application (NDA) to the National Medical Products Administration (NMPA) of China for ELAHERE in FRα-positive PROC to support approval and launch.
    • Announced collaboration with Takeda Pharmaceutical Company Limited (Takeda) granting Takeda an exclusive license to develop and commercialize ELAHERE in Japan. The Company received an upfront payment of $23.21 million and is eligible to receive up to approximately $1352 million in regulatory and commercial milestone payments in addition to tiered royalties in the low double-digits to mid-twenties.

    Clinical Pipeline and Research

    • Presented additional subset analyses in prior lines of therapy and prior exposure to PARP inhibitor (PARPi) therapy from MIRASOL in an oral session at the 24th Congress of the European Society of Gynaecological Oncology (ESGO) demonstrating clinical outcomes of safety and efficacy consistent with the overall MIRASOL study population.
    • Reported that PICCOLO, the ongoing single-arm Phase 2 trial of mirvetuximab in FRα-high, platinum-sensitive ovarian cancer (PSOC) has met the primary endpoint of objective response rate (ORR) based upon an interim assessment with no new safety signals identified. An ORR of at least 48% is expected when full data are reported in mid-2024.
    • Established a multi-target license and option agreement with ImmunoBiochem Corporation to develop next-generation ADCs.

    Corporate

    • Appointed Lauren White as Senior Vice President and Chief Financial Officer, and Heather Adkins Huet, PhD, as Senior Vice President and Chief Scientific Officer.

    ANTICIPATED UPCOMING EVENTS

    • Potential FDA approval of ELAHERE's sBLA in H1 2024.
    • Report full data from the single-arm Phase 2 PICCOLO trial of mirvetuximab in FRα-high PSOC in mid-2024.
    • Potential EMA approval of ELAHERE in late 2024 to support launch in Europe.
    • Our partner, Huadong Medicine, is planning for NMPA approval of ELAHERE by the end of 2024 to support launch in China.
    • Report data from the 802 trial, evaluating the pivekimab sunirine (pivekimab) triplet with Venclexta® (venetoclax) and Vidaza® (azacitidine) in frontline acute myeloid leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting in December 2023.
    • Report top-line data from the pivotal frontline de novo cohort in the Phase 2 CADENZA trial of pivekimab in blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 2024.
    • Provide an update on the IMGC936 non-small cell lung cancer (NSCLC) cohort following a prespecified interim analysis.

    FINANCIAL RESULTS

    Total revenues were $113.4 million for the quarter ended September 30, 2023, including $105.2 million of net product revenues from sales of ELAHERE, compared to $15.4 million in total revenues for the quarter ended September 30, 2022. The increase was driven by ELAHERE net sales, partially offset by $7.4 million of license fees recorded as revenue in the prior year period pursuant to the Company's collaboration agreements with Eli Lilly and Company and Novartis Institutes for BioMedical Research, Inc.

    Research and development expenses were $47.6 million for the quarter ended September 30, 2023 compared to $59.2 million for the quarter ended September 30, 2022. The decrease was primarily driven by ELAHERE supply costs expensed in the prior quarter versus capitalized in the current period and lower hiring expenses. Partially offsetting these decreases, salaries and benefits increased driven largely by the expansion of our medical affairs organization.

    Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022. The increase was due primarily to greater expenses in support of the US launch of ELAHERE, including costs related to the addition of our commercial organization and sales and marketing activities.

    Net income for the third quarter of 2023 was $30.7 million, or $0.10 per basic and diluted share, compared to a net loss of $77.8 million, or $0.31 per basic and diluted share, for the third quarter of 2022.

    ImmunoGen had $605.5 million in cash and cash equivalents and $130.7 million in accounts receivable as of September 30, 2023, compared with $275.1 million in cash and cash equivalents and $12.6 million in accounts receivable as of December 31, 2022. Cash used in operations was $137.7 million for the first nine months of 2023 compared with cash used in operations of $169.6 million for the same period in 2022. Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.

    FINANCIAL GUIDANCE

    ImmunoGen's full year financial guidance for 2023 remains unchanged; the Company continues to expect:

    • revenues, excluding product revenue from ELAHERE, between $45 million and $50 million; and
    • operating expenses between $350 million and $365 million.

    The Company continues to expect that its existing cash and cash equivalents, together with anticipated future product and collaboration revenues, will fund operations for more than two years.

    CONFERENCE CALL INFORMATION

    ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location.

    ABOUT ELAHERE

    ELAHERE® (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.

    ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

    This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Eye problems are common with ELAHERE and can be severe. ELAHERE also can cause severe or life-threatening inflammation of the lungs that may lead to death and patients may develop nerve problems called peripheral neuropathy during treatment. Please see full Prescribing Information, including Boxed Warning, and Medication Guide for ELAHERE.

    ABOUT IMMUNOGEN

    ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

    Learn more about who we are, what we do, and how we do it at www.immunogen.com.

    Vidaza® and Venclexta® are registered trademarks of their respective owners. ELAHERE® is a registered trademark of ImmunoGen, Inc.

    1 ¥3.4 billion (0.0068 exchange rate as of September 5, 2023); 2 ¥19.9 billion (0.0068 exchange rate as of August 25, 2023)

    FORWARD-LOOKING STATEMENTS

    This press release includes forward-looking statements. These statements include, but are not limited to, the timing and outcome of the submissions of a Marketing Authorization Application in Europe, a supplemental Biologics License Application in the US, and a New Drug Application in China; the potential development and commercialization of ELAHERE in Japan; the timing and presentation of clinical data on the Company's products and product candidates, including data from the PICCOLO trial, the pivekimab triplet, top-line data from the Phase 2 CADENZA trial, and IMGC936; the Company's revenues and operating expenses for 2023; the Company's anticipated cash runway; and the Company's future product and collaboration revenues. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the successful execution of the collaboration with Takeda and their development and commercialization efforts; the timing and outcome of the Company's clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of clinical trials and regulatory processes; the timing and outcome of anticipated interactions with regulatory authorities; the risk that the Company may not be able to obtain adequate price and reimbursement for any approved products, including the potential for delays or additional difficulties for ELAHERE in light of the FDA granting accelerated approval; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2023, the Company's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on April 28, 2023 and July 31, 2023, and other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this press release. ImmunoGen undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

     
    IMMUNOGEN, INC.
    SELECTED FINANCIAL INFORMATION
    (in thousands, except per share amounts)
     
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Unaudited)
     
    September 30, December 31,

    2023

    2022

    ASSETS
     
    Cash and cash equivalents  $

    605,535

    $

    275,138

    Accounts receivable

    130,694

    12,596

    Inventory

    33,768

    16,196

    Other assets  

    52,104

     

    45,006

     
    Total assets $

    822,101

    $

    348,936

     
    LIABILITIES AND SHAREHOLDERS' EQUITY
     
    Current portion of deferred revenue $

    37,186

    $

    13,856

    Other current liabilities

    97,474

    108,002

    Term loan, net

    72,113

                             -  

    Long-term portion of deferred revenue

    26,718

    36,355

    Other long-term liabilities

    27,014

    34,897

    Shareholders' equity  

    561,596

     

    155,826

     
    Total liabilities and shareholders' equity $

    822,101

    $

    348,936

     
     
     
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Unaudited)
    Three Months Ended Nine Months Ended
    September 30, September 30,
     

    2023

       

    2022

     

    2023

       

    2022

     
    Revenues:
    Product revenue, net $

                105,164

    $

                             -  

    $

            212,079

    $

                           -  

    License and milestone fees

                          51

                      7,382

              15,122

                  45,247

    Non-cash royalty revenue

                    7,355

                      7,993

              17,936

                  21,537

    Research and development support  

                        855

     

                             -  

     

                1,310

     

                       831

     
    Total revenues  

                113,425

     

                    15,375

     

            246,447

     

                  67,615

     
    Cost and operating expenses:
    Cost of sales

                    2,155

                             -  

                3,690

                           -  

    Research and development 

                  47,570

                    59,181

            149,267

                154,885

    Selling, general and administrative   

                  37,744

     

                    33,623

     

            114,116

     

                  74,064

     
    Total cost and operating expenses  

                  87,469

     

                    92,804

     

            267,073

     

                228,949

     
     Income (loss) from operations

                  25,956

                   (77,429)

             (20,626)

              (161,334)

     
    Interest income (expense), net

                    4,844

                      1,539

                8,918

                    2,183

    Non-cash interest expense on liability related to sale of future royalty and term loan

                   (1,054)

                        (867)

               (2,986)

                   (3,194)

    Other loss, net  

                      (164)

     

                        (998)

     

                  (109)

     

                   (1,576)

     
    Income (loss) before income taxes $

                  29,582

    $

                   (77,755)

    $

             (14,803)

    $

              (163,921)

     
    Income tax benefit 

                    1,166

                             -  

                    289

                           -  

     
    Net income (loss)  

                  30,748

     

                   (77,755)

     

             (14,514)

     

              (163,921)

     
    Net income (loss) per common share - basic $

                       0.10

    $

                       (0.31)

    $

                 (0.05)

    $

                     (0.65)

     
    Net income (loss) per common share - diluted $

                       0.10

    $

                       (0.31)

    $

                 (0.05)

    $

                     (0.65)

     
    Weighted-average common shares outstanding - basic  

                273,341

     

                  253,511

     

            265,265

     

                253,371

     
    Weighted-average common shares outstanding - diluted  

                287,590

     

                  253,511

     

            265,265

     

                253,371

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231102828508/en/

    Get the next $IMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMGN

    DatePrice TargetRatingAnalyst
    12/1/2023$25.00 → $31.00Buy → Neutral
    Guggenheim
    11/20/2023$17.00Neutral
    Goldman
    11/9/2023$25.00Buy
    Deutsche Bank
    10/6/2023$16.00Perform
    Oppenheimer
    5/3/2023$6.00 → $16.00Neutral → Overweight
    Piper Sandler
    11/21/2022$10.00Buy
    Truist
    9/9/2022$8.00Overweight
    Barclays
    3/21/2022$9.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $IMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2024 - FDA Roundup: March 26, 2024

      For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

      3/26/24 3:38:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

      3/22/24 1:48:21 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

      11/15/22 5:01:07 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mitchell Dean J returned 103,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:48:55 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Peterson Kristine

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:48:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thackray Helen M. returned 3,074 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:47:26 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    SEC Filings

    See more
    • SEC Form 15-12G filed by ImmunoGen Inc.

      15-12G - ImmunoGen, Inc. (0000855654) (Filer)

      2/22/24 4:15:19 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by ImmunoGen Inc.

      S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

      2/12/24 4:33:11 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by ImmunoGen Inc.

      S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

      2/12/24 4:32:20 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ImmunoGen downgraded by Guggenheim with a new price target

      Guggenheim downgraded ImmunoGen from Buy to Neutral and set a new price target of $31.00 from $25.00 previously

      12/1/23 7:33:23 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on ImmunoGen with a new price target

      Goldman initiated coverage of ImmunoGen with a rating of Neutral and set a new price target of $17.00

      11/20/23 7:31:54 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on ImmunoGen with a new price target

      Deutsche Bank initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $25.00

      11/9/23 6:40:12 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen's Senior Vice President and Chief Financial Officer, the compensation committee of the Company's Board of Directors (the "Compensation Committee") approved grants of non-qualified stock options to purchase 295,975 shares of its common stock and restricted stock units ("RSUs") covering 51,625 shares of its common stock under the Inducement Plan to Ms. White. The Inducement Plan is used exclusively for the grant of equity awards t

      9/18/23 5:00:00 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

      New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical is released when the ADC attaches to its intended target (a cancer protein or receptor). Linkers, drugs or poisons, monoclonal antibodies, and others are among the most prevalent types of antibody-drug conjugates. A single white blood cell is cloned in order to produce monoclonal antibodies. Each successive antibody produced in this m

      1/22/25 11:05:00 AM ET
      $IMGN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IMGN
    Financials

    Live finance-specific insights

    See more
    • AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

      Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancerELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancerImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignanciesTransaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billionAbbVie to hold an investor conference call at 8:00 a.m. CTNORTH CHICAGO

      11/30/23 7:30:00 AM ET
      $ABBV
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

      Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024 Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer Conference Call to be Held at 8:00 a.m. E

      11/2/23 6:30:00 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

      ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN

      10/19/23 4:01:00 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 5:01:40 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 4:26:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/13/24 5:06:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care